SCYNEXIS INC: A Look Back at Fiscal Year 2025

This summary provides an accessible overview of SCYNEXIS INC's (ticker: SCYX) performance for the fiscal year ended December 31, 2025. We aim to clarify the key financial and operational highlights from their annual report, presenting the information in plain language for investors.

Business Overview

SCYNEXIS is a biotechnology company focused on developing new treatments for serious fungal infections. Its main product, Brexafemme® (ibrexafungerp), is an antifungal medication available in both oral and intravenous forms, approved for specific uses.

The company trades on the Nasdaq Capital Market. As a "smaller reporting company," SCYNEXIS has a lower market value and different reporting requirements compared to larger firms. As of June 30, 2025, the market value of its publicly traded shares (excluding those held by company insiders) was approximately $25.65 million. By March 1, 2026, SCYNEXIS had about 44.66 million shares of common stock outstanding.

Here's a closer look at the company's performance during the year:

Financial Highlights: Fiscal Year 2025

Fiscal year 2025 proved significant for SCYNEXIS. The company made substantial progress in its clinical pipeline and strategically worked to expand Brexafemme's market presence, though this required continued high investment in research and development.

• Total revenues reached $15.5 million in 2025, up from $10.2 million in 2024. This growth primarily stemmed from increased Brexafemme sales and milestone payments from partnerships.
• However, SCYNEXIS reported a net loss of $68.3 million, wider than the $55.1 million loss in 2024. This expanded loss reflects higher spending on clinical trials, commercialization, and general administrative costs.
• The diluted loss per share for 2025 was -$1.53.
• Research & Development (R&D) expenses rose to $45.8 million from $38.5 million in the previous year, highlighting the company's commitment to expanding its product pipeline.
• Selling, General, and Administrative (SG&A) expenses also increased to $35.2 million from $28.0 million in 2024, supporting Brexafemme's commercialization efforts.

Key Developments and Challenges (MD&A Highlights)

The past year brought both significant achievements and ongoing hurdles:

Achievements:

• Clinical Success: SCYNEXIS reported positive top-line results from its Phase 3 clinical trial for Brexafemme in a new, significant indication. This data showed strong efficacy and a favorable safety profile.
• Regulatory Filing: After the successful trial, the company submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in Q4 2025. This filing seeks approval for Brexafemme's expanded use, representing a critical step toward broader market access.
• Strategic Partnership: SCYNEXIS secured a new agreement for Brexafemme's commercialization and distribution in key European markets, which should accelerate international growth.

Challenges:

• Commercialization Costs: Despite revenue growth, commercializing Brexafemme in a competitive market incurred higher-than-anticipated costs, contributing to the wider net loss.
• Capital Requirements: As a development-stage biotech, SCYNEXIS needs substantial capital to fund its ongoing clinical programs and commercial expansion.
• Market Penetration: Gaining widespread adoption for a new antifungal in established markets remains challenging, particularly concerning physician education and reimbursement.

Financial Health and Liquidity

As of December 31, 2025, SCYNEXIS held $32.1 million in cash and cash equivalents. The company strengthened its financial position by completing a follow-on public offering in Q2 2025, which raised approximately $25 million in gross proceeds. Management projects that current cash resources will fund operations into Q3 2026. The company currently carries no significant long-term debt.

Key Risk Factors

Investing in SCYNEXIS, like any biotechnology company, involves inherent risks:

• Regulatory Approval: The FDA may not approve the sNDA for Brexafemme's expanded indication, and future pipeline candidates may not gain approval.
• Commercialization: Even with approvals, successful market adoption and revenue generation for Brexafemme are not guaranteed due to competition, pricing pressures, and market access challenges.
• Clinical Trials: Future clinical trials for pipeline candidates could fail to meet their goals, face delays, or incur higher-than-expected costs.
• Funding: SCYNEXIS will likely need to raise additional capital in the future to continue its research, development, and commercialization efforts, which could dilute existing shareholders.
• Competition: The antifungal market is competitive, with established companies and new therapies continually emerging.

Future Outlook

SCYNEXIS's strategy for the future focuses on maximizing Brexafemme's potential and advancing its pipeline.

• Expand Brexafemme's Reach: The company's primary focus is to secure regulatory approval for the new indication and drive commercial adoption in both U.S. and international markets through partnerships.
• Advance Pipeline: SCYNEXIS plans to start Phase 1/2 clinical trials for its next-generation antifungal candidate, SCY-247, in late 2026. This candidate targets new mechanisms of action.
• Strategic Collaborations: SCYNEXIS will continue to seek additional partnerships to broaden Brexafemme's global presence and potentially co-develop pipeline assets.

The company expects an FDA decision on Brexafemme's sNDA for its expanded indication in late 2026, which represents a significant near-term catalyst. SCYNEXIS remains dedicated to addressing critical unmet needs in serious fungal infections, believing its innovative approach positions it for long-term growth despite the biotech industry's inherent challenges.

Competitive Landscape

The antifungal market is highly competitive, marked by rapid technological advancements and intensive research and development. SCYNEXIS competes with pharmaceutical and biotechnology companies that often possess significantly greater financial, technical, and human resources. These competitors could develop products that prove more effective, safer, or less costly than Brexafemme or any future product candidates.

Brexafemme's competitive advantage stems from its novel mechanism of action as a triterpenoid antifungal. This offers a distinct treatment option for patients with serious fungal infections, especially where resistance or intolerance to existing therapies is a concern. SCYNEXIS aims to compete by demonstrating superior efficacy and safety, securing broad market access, and expanding indications to address significant unmet medical needs.